Skip to main content
          Skip to FDA Search
          Skip to in this section menu
          Skip to footer links


U.S. flagAn official website of the United States government

					Here’s how you know
          			Dot gov**The .gov means it’s official.**Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
							      SSL**The site is secure.** The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. 
			U.S. Food and Drug Administration
				
        Search
            Menu
							
						Search FDA
									
									Submit search 
		Featured
							Contact FDA
	                FDA Guidance Documents
	                Recalls, Market Withdrawals and Safety Alerts
	                Press Announcements
	                Warning Letters
	                Advisory Committees
	                En Español

					Products
            Food
							Drugs
							Medical Devices
							Radiation-Emitting Products
							Vaccines, Blood, and Biologics
							Animal and Veterinary
							Cosmetics
							Tobacco ProductsTopics
            About FDA
							Combination Products
							Regulatory Information
							Safety
							Emergency Preparedness
							International Programs
							News and Events
							Training and Continuing Education
							Inspections and Compliance
							Science and ResearchInformation For
            Consumers
	            Patients
	            Industry
	            Health Professionals
	            Federal, State and Local Officials 
 In this section:

                CFSAN Constituent Updates

CFSAN Constituent Updates Home
          Food
          News & Events from CFSAN
          CFSAN Constituent Updates
          FDA to Continue Providing Flexibility to Infant Formula Manufacturers Under Certain Conditions to Stabilize SuppliesCFSAN Constituent Updates FDA to Continue Providing Flexibility to Infant Formula Manufacturers Under Certain Conditions to Stabilize Supplies
  
  	
    Subscribe to Email Updates
    Share
    Post
    Linkedin

    Email
    PrintConstituent Update

September 30, 2022

Today the U.S. Food and Drug Administration issued a **guidance** announcing the agency’s plans to provide a pathway for manufacturers of infant formula under enforcement discretion to market infant formula products that may not currently comply with specific FDA requirements while they work toward meeting those requirements. The guidance balances the need to ensure that infant formula products meet regulatory requirements with the need for a more resilient infant formula supply.

In May 2022, the FDA issuedguidance announcing that it was exercising temporary enforcement discretion, on a case-by-case basis, for certain requirements that apply to infant formula. Since the publication of the May 2022 guidance, many manufacturers have provided to FDA detailed information pertaining to particular infant formulas, and the FDA has carefully reviewed such information, including details about the products’ nutritional adequacy and safety, microbiological testing results, labeling information and details about the manufacturing facility’s food safety production practices and inspection history.  Based on those reviews, FDA has issued letters of enforcement discretion related to the marketing of specific infant formula products in the United States through November 14, 2022. Under the new guidance, the period of enforcement discretion for those products identified in the letters of enforcement discretion will be extended until Jan. 6, 2023, with further extensions possible for firms that express interest in and take steps toward the lawful marketing of such products in the United States.

The disruption of infant formula supplies, caused in part by the temporary shutdown of a major infant formula manufacturing facility, has demonstrated the need to create a more resilient U.S. supply for infant formula products and help avoid future shortages.  While the infant formula supply continues to improve, continued product availability is desirable for infants who started on a specific formula during the shortage and now are accustomed to that formula as an essential source of nutrition.

Flexibility to continue to market infant formula that may not comply with specific FDA requirements will be considered only in certain circumstances.  Manufacturers currently marketing their products in the U.S. under enforcement discretion would need to send to the FDA by Dec. 5, 2022, a letter of intent to pursue  compliance with all regulatory requirements.  The FDA would evaluate each letter of intent, and where appropriate, issue a new letter of enforcement discretion by Jan. 6, 2023, to clarify that FDA intends to continue exercising enforcement discretion over the distribution of such products while the manufacturer works to bring its products into full compliance.

The guidance provides a recommended timetable for the actions manufacturers will be taking to achieve compliance with all requirements that apply to their products. In addition, the FDA will host industry webinars to provide an overview and answer questions on the recently released guidance to infant formula manufacturers. More information on the webinars will be released shortly.

**For more information:**

Guidance for Industry: Infant Formula Transition Plan for Exercise of Enforcement Discretion
	Press Release: FDA Pathway Supports Long-Term Stability, Diversity of Safe and Nutritious Infant Formula Supply in the U.S.
	Enforcement Discretion to Manufacturers to Increase Infant Formula Supplies
	Resources for Parents and Caregivers on Imported Infant Formula

                                                                                  Content current as of:
      09/30/2022
              
              
Regulated Product(s)
		 Food & Beverages
			  			     			  						              
			
			
			
			
			
						  Infant Formula & FoodsCFSAN Constituent Updates
 Subscribe to CFSAN Constituent Updates
                        Get email updates delivered to your inbox.
    Enter your email address to subscribe:
 Footer Links
    FDA Archive
          About FDA
          Accessibility
      Visitor Information
          Website Policies / Privacy
          No FEAR Act
          Vulnerability Disclosure Policy
      FOIA
          HHS.gov
          USA.gov
    Contact FDA
      Follow FDA on Facebook
      Follow FDA on X
      Follow FDA on Instagram
      Follow FDA on LinkedIn
      View FDA videos on YouTube
      Subscribe to FDA RSS feeds
    FDA Homepage
    Contact Number
      1-888-INFO-FDA (1-888-463-6332) Back toTop